Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), R1 RCM (RCM) and Gilead Sciences (GILD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teladoc (TDOC – Research Report), R1 RCM (RCM – Research Report) and Gilead Sciences (GILD – Research Report).

Teladoc (TDOC)

In a report issued on April 25, Vikram Kesavabhotla from Robert W. Baird maintained a Hold rating on Teladoc, with a price target of $16.00. The company’s shares closed last Monday at $13.39, close to its 52-week low of $12.65.

According to TipRanks.com, Kesavabhotla has 0 stars on 0-5 stars ranking scale with an average return of -5.6% and a 35.5% success rate. Kesavabhotla covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Doximity, and R1 RCM.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $18.41 average price target, representing a 39.9% upside. In a report issued on April 11, Leerink Partners also maintained a Hold rating on the stock with a $17.00 price target.

See today’s best-performing stocks on TipRanks >>

R1 RCM (RCM)

Leerink Partners analyst Michael Cherny maintained a Buy rating on R1 RCM yesterday and set a price target of $17.00. The company’s shares closed last Monday at $12.35.

According to TipRanks.com, Cherny is a 4-star analyst with an average return of 4.5% and a 49.5% success rate. Cherny covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Patterson Companies, and Hims & Hers Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for R1 RCM with a $16.64 average price target, implying a 35.3% upside from current levels. In a report issued on April 18, RBC Capital also maintained a Buy rating on the stock with a $19.00 price target.

Gilead Sciences (GILD)

In a report issued on April 26, Brian Skorney from Robert W. Baird maintained a Hold rating on Gilead Sciences, with a price target of $80.00. The company’s shares closed last Monday at $65.94, close to its 52-week low of $64.63.

According to TipRanks.com, Skorney is a 2-star analyst with an average return of -0.1% and a 43.3% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $82.95, a 27.0% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Hold rating on the stock with a $82.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TDOC:

• Teladoc price target lowered to $15 from $16 at TD Cowen
• Teladoc price target lowered to $25 from $28 at Canaccord
• Teladoc price target lowered to $18 from $25 at RBC Capital
• Teladoc price target lowered to $16 from $20 at UBS
• Teladoc price target lowered to $20 from $25 at Barclays